Overactivity of glutamatergic transmission has been implicated in
Parkinson's disease (PD) and
levodopa (
L-Dopa)-induced
dyskinesias. Striatal
metabotropic glutamate receptors type 5 (mGluR5) are abundant and provide specific targets to modulate glutamatergic activity. This study investigated the acute effects of the novel mGluR5 antagonist
AFQ056 on motor behavior in
L-Dopa-treated monkeys with a
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (
MPTP) lesion to model PD. Six Macaca fascicularis
MPTP monkeys were treated repeatedly with
L-Dopa; this treatment increased their locomotion and reduced their parkinsonian scores, but also induced
dyskinesias. When
AFQ056 (doses of 5, 25, 125 or 250mg/kg) was administered one hour prior to a high dose of
L-Dopa, the antiparkinsonian activity of
L-Dopa was maintained as measured with locomotion and antiparkinsonian scores, whereas
dyskinesias were significantly reduced at 25, 125 and 250mg/kg
AFQ056 for peak
dyskinesia score and
at 125 and 250mg/kg for the 1h peak period of
dyskinesia score. Administration of
AFQ056 one hour before
L-Dopa led to peak or elevated plasma
AFQ056 concentrations occurring close to
L-Dopa peak-dose
dyskinesias. We next investigated
AFQ056 25mg/kg combined with a low dose of
L-Dopa. The antiparkinsonian activity of
L-Dopa was increased as measured with locomotion, while
dyskinesias remained low at these doses. Our results show a beneficial motor effect of
AFQ056 with
L-Dopa in
MPTP monkeys. This supports the
therapeutic use of an mGluR5 antagonist to restore normal glutamatergic neurotransmission in PD and decrease
dyskinesias.